|
|
Post by mnlearner on Jan 11, 2022 16:48:46 GMT -5
YES! Thank you so much.
|
|
|
|
Post by peppy on Jan 12, 2022 16:10:25 GMT -5
That was Chitty. Omicron is less deadly and biotech sells off. MNKD Nasdaq real time volume, 2,687,426 shares. MNKD Nasdaq summary volume, 3,984,910 Avg. Volume 2,585,792 $3.85 -0.25 -6.1% Not sure why the chart is showing $3.89, should be $3.85.  |
|
|
|
Post by mytakeonit on Jan 12, 2022 16:25:57 GMT -5
After hours is at $3.89
|
|
|
|
Post by prcgorman2 on Jan 12, 2022 19:55:58 GMT -5
I added to the volume, because I took MTOI’s advice and added “cheap shares”. I didn’t get them at the bottom, but I was happy to add. If this is a trend, I’m going to buy even more shares, and be grateful for the bargain. I have a lot of faith that TreT is going to get approved and that we should expect a substantial upside. The Zacks auto-generated piece indicated most analysts had buy ratings with north of $6 targets. I agree with that. (I also half-expect those ratings to be revised downwards until the FDA approves TreT because analysts like for their targets to be exceeded.)
|
|
|
|
Post by Clement on Jan 12, 2022 20:26:53 GMT -5
I added to the volume, because I took MTOI’s advice and added “cheap shares”. I didn’t get them at the bottom, but I was happy to add. If this is a trend, I’m going to buy even more shares, and be grateful for the bargain. I have a lot of faith that TreT is going to get approved and that we should expect a substantial upside. The Zacks auto-generated piece indicated most analysts had buy ratings with north of $6 targets. I agree with that. (I also half-expect those ratings to be revised downwards until the FDA approves TreT because analysts like for their targets to be exceeded.) Me, too. I added. |
|
|
|
Post by markado on Jan 12, 2022 21:03:47 GMT -5
I added to the volume, because I took MTOI’s advice and added “cheap shares”. I didn’t get them at the bottom, but I was happy to add. If this is a trend, I’m going to buy even more shares, and be grateful for the bargain. I have a lot of faith that TreT is going to get approved and that we should expect a substantial upside. The Zacks auto-generated piece indicated most analysts had buy ratings with north of $6 targets. I agree with that. (I also half-expect those ratings to be revised downwards until the FDA approves TreT because analysts like for their targets to be exceeded.) Me, too. I added. I'm tapped at the moment, but wish I had an extra $40K to take 10,000 more shares off the table. I may have to check the couch cushions and under the mattress, to see what I can pull off. |
|
|
|
Post by mytakeonit on Jan 12, 2022 21:07:37 GMT -5
I'm not buying any ... I already have enough shares. When pps climbs ... I won't know what to do with all this money anyway. I already have a lifetime of wine in my house.  Average pps is under $2. But, that's mytakeonit |
|
|
|
Post by nylefty on Jan 12, 2022 23:11:33 GMT -5
I added to the volume, because I took MTOI’s advice and added “cheap shares”. Me, too. I added. So did I. |
|
|
|
Post by mytakeonit on Jan 13, 2022 1:20:46 GMT -5
Okay ... stop buying when you have 1M shares.
But, that's mytakeonit
|
|
|
|
Post by peppy on Jan 13, 2022 9:47:49 GMT -5
MNKD volume this morning is huge, relatively for MNKD
@ 15 mins of trade,
real time, 223,158
summary, 331,812
Avg. Volume 2,609,266
$3.845
-0.005
added, 30 mins of trade,
real time, 294,790
summary, 474,235
$3.895
+0.045
added, 1 hour of trade.
real time, 396,484
summary, 636,005
$3.87
+0.02
|
|
|
|
Post by peppy on Jan 13, 2022 16:06:07 GMT -5
MNKD volume this morning is huge, relatively for MNKD @ 15 mins of trade, real time, 223,158 summary, 331,812 Avg. Volume 2,609,266 $3.845 -0.005 added, 30 mins of trade, real time, 294,790 summary, 474,235 $3.895 +0.045 added, 1 hour of trade. real time, 396,484 summary, 636,005 $3.87 +0.02 MNKD Nasdaq real time volume, 2,104,623 shares. MNKD Nasdaq summary volume, 3,019,148 shares. $3.76. -0.09 (-2.34%) At close: 04:00PM EST Added a weekly charts so visualize support and resistance.  Monthly  |
|
|
|
Post by peppy on Jan 14, 2022 16:13:48 GMT -5
MNKD Nasdaq real time volume, 2,174,494 shares. MNKD Nasdaq summary volume, 2,909,923 Avg. Volume 2,613,074 $3.92. +0.16 (+4.26%) Price hit $3.945, $3.94 was yesterdays high. Price needs to take out the $4.05 MNKD WEEKLY  UTHR ended the day at highs as well, attempting a break out once again. UTHR MONTHLY  MNKD on the other hand its monthly chart, price just tested the 20 month MA @ $3.676. Last touched 16 months ago. Have a nice weekend. |
|
|
|
Post by prcgorman2 on Jan 14, 2022 22:33:21 GMT -5
Good volume. And UTHR is very close to an all-time high. It appears the Street is unconcerned about TreT (at least as far as UTHR is concerned).
|
|
|
|
Post by peppy on Jan 18, 2022 8:22:43 GMT -5
MNKD has volume this pre-market morning. With a hour and 10 mins to go, premarket MNKD showing, Pre-Market Volume 8,983 3.95. +0.03 (+0.77%) Posted by brianroccoClass 1 Response!! Hot off the press: On October 18, 2021, United Therapeutics Corporation (the Company) issued a press release disclosing that it had received a Complete Response from the U.S. Food and Drug Administration (the FDA) concerning the Company’s new drug application (NDA) for Tyvaso DPI™. On December 27, 2021, the Company disclosed that it had resubmitted the NDA to the FDA. Today, the Company discloses that the FDA has acknowledged acceptance of the NDA for review as a class 1 response with a user fee goal date in February 2022. |
|
|
|
Post by prcgorman2 on Jan 18, 2022 8:42:38 GMT -5
MNKD has volume this pre-market morning. With a hour and 10 mins to go, premarket MNKD showing, Pre-Market Volume 8,983 3.95. +0.03 (+0.77%) Posted by brianrocco Class 1 Response!! Hot off the press: On October 18, 2021, United Therapeutics Corporation (the Company) issued a press release disclosing that it had received a Complete Response from the U.S. Food and Drug Administration (the FDA) concerning the Company’s new drug application (NDA) for Tyvaso DPI™. On December 27, 2021, the Company disclosed that it had resubmitted the NDA to the FDA. Today, the Company discloses that the FDA has acknowledged acceptance of the NDA for review as a class 1 response with a user fee goal date in February 2022. Nice!! www.morningstar.com/news/dow-jones/202201185424/united-therapeutics-fda-acknowledges-acceptance-of-tyvaso-dpi-application |
|
